# Efficacy Safety and Tolerability of Multiple Doses of Oshadi Icp (Oshadi Oral Insulin) in Patients With Type 1 Diabetes Mellitus - Phase II Clinical Study

> **NCT01973920** · PHASE2 · COMPLETED · sponsor: **Oshadi Drug Administration** · enrollment: 12 (actual)

## Conditions studied

- Diabetes Mellitus
- Insulin-Dependent
- Type 1

## Interventions

- **DRUG:** Oshadi Icp

## Key facts

- **NCT ID:** NCT01973920
- **Lead sponsor:** Oshadi Drug Administration
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2017-02
- **Final completion:** 2017-02
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2018-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01973920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01973920, "Efficacy Safety and Tolerability of Multiple Doses of Oshadi Icp (Oshadi Oral Insulin) in Patients With Type 1 Diabetes Mellitus - Phase II Clinical Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01973920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*